Literature DB >> 35350791

Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.

Han Zhang1, Jing Kan1, Caojing Zhang2, Zhenweng Yang3, Heping Gu4, Fenling Fan5, Hong Gu6, Qiguang Wang7, Juan Zhang1, Dujiang Xie1, Gangcheng Zhang8, Xiaomei Guo9, Yuehui Yin10, Shao-Liang Chen1.   

Abstract

Aims: This study aimed to assess the long-term effects of pulmonary artery denervation (PADN) on mortality in patients with pulmonary arterial hypertension (PAH). Methods and results: Between March 2012 and March 2018, a total of 120 patients with PAH, who underwent PADN treatment and were prospectively followed up, were analysed. Patients were classified into World Health Organization (WHO) Functional Class I and II (FC 1-2; n=46) and Functional Class III and IV (FC 3-4; n=74) according to their FC prior to PADN. The primary endpoint was lung transplantation-free mortality until March 2021. The secondary endpoint was a change in the six-minute walk distance (6MWD). During the median of 4.8 years of follow-up, 23 (19.2%) patients died, predominantly from the FC 3-4 group (25.7%), compared to 8.7% in the FC 1-2 group (p=0.034). The mortality rate at one year (2.2% vs 12.2%, p=0.087) and three years (6.5% vs 17.6%, p=0.102) was numerically low in the FC 1-2 group versus the FC 3-4 group, respectively. The median net increase of 6MWD was +29 m in the FC 1-2 group, compared to +60.5 m in the FC 3-4 group (p=0.037). Conclusions: PADN results in significant improvements in survival at long-term follow-up, especially in patients with PAH in FC 3-4. This study was the continuation of the PADN-1 study which was registered at URL: http://www.chictr.trc.com.cn. Unique identifier: chiCTR-ONC-12002085.

Entities:  

Year:  2022        PMID: 35350791      PMCID: PMC8922462          DOI: 10.4244/AIJ-D-21-00033

Source DB:  PubMed          Journal:  AsiaIntervention        ISSN: 2426-3958


  29 in total

Review 1.  End points and clinical trial design in pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; David B Badesch; Marion Delcroix; Thomas R Fleming; Sean P Gaine; Nazzareno Galiè; J Simon R Gibbs; Nick H Kim; Ronald J Oudiz; Andrew Peacock; Steeve Provencher; Olivier Sitbon; Victor F Tapson; Werner Seeger
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements.

Authors:  C Tei; R A Nishimura; J B Seward; A J Tajik
Journal:  J Am Soc Echocardiogr       Date:  1997-03       Impact factor: 5.251

3.  Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study.

Authors:  Hang Zhang; Juan Zhang; Mengxuan Chen; Du-Jiang Xie; Jing Kan; Wande Yu; Xiao-Bo Li; Tian Xu; Yue Gu; Jianzeng Dong; Hong Gu; Yaling Han; Shao-Liang Chen
Journal:  JACC Cardiovasc Interv       Date:  2018-10-23       Impact factor: 11.195

4.  Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry.

Authors:  Roberto Del Pozo; Isabel Blanco; Ignacio Hernández-González; Manuel López-Meseguer; Raquel López-Reyes; María Lázaro-Salvador; Teresa Elías-Hernández; Pablo Álvarez-Vega; Gregorio Miguel Pérez-Peñate; Amaya Martínez-Meñaca; Pedro Bedate; Pilar Escribano-Subias
Journal:  Int J Cardiol       Date:  2018-10-05       Impact factor: 4.164

Review 5.  Pharmacotherapeutic management of pulmonary arterial hypertension.

Authors:  Joe R Anderson; James J Nawarskas
Journal:  Cardiol Rev       Date:  2010 May-Jun       Impact factor: 2.644

6.  Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension).

Authors:  Shao-Liang Chen; Feng-Fu Zhang; Jing Xu; Du-Jiang Xie; Ling Zhou; Thach Nguyen; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

7.  Increased sympathetic nerve activity in pulmonary artery hypertension.

Authors:  Sonia Velez-Roa; Agnieszka Ciarka; Boutaina Najem; Jean-Luc Vachiery; Robert Naeije; Philippe van de Borne
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

8.  Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.

Authors:  Robyn J Barst; Lorinda Chung; Roham T Zamanian; Michelle Turner; Michael D McGoon
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

9.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

10.  Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy.

Authors:  Alexander Romanov; Alexander Cherniavskiy; Nataliya Novikova; Alexander Edemskiy; Dmitry Ponomarev; Vitaliy Shabanov; Denis Losik; Dmitry Elesin; Ilya Stenin; Igor Mikheenko; Roman Zhizhov; Evgeny Kretov; Evgeny Pokushalov; Sunny S Po; Tamila V Martynyuk; Jonathan S Steinberg
Journal:  J Am Coll Cardiol       Date:  2020-08-25       Impact factor: 24.094

View more
  1 in total

Review 1.  Current status of pulmonary artery denervation.

Authors:  Mark G Davies; Dimitrios Miserlis; Joseph P Hart
Journal:  Front Cardiovasc Med       Date:  2022-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.